紫杉醇及其在卵巢癌治疗中不断演变的作用。
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.
作者信息
Kampan Nirmala Chandralega, Madondo Mutsa Tatenda, McNally Orla M, Quinn Michael, Plebanski Magdalena
机构信息
Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia ; Gynaeoncology Unit, Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia.
Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia.
出版信息
Biomed Res Int. 2015;2015:413076. doi: 10.1155/2015/413076. Epub 2015 Jun 7.
Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
紫杉醇是一类具有微管稳定能力的紫杉烷，一直与铂类疗法一起，作为原发性卵巢癌治疗的标准护理方法。对免疫基础和其他潜在作用机制的更深入理解，以及新的给药方案和/或给药途径，可能会增强其临床益处。具有更好安全性和更高肿瘤内细胞毒性的新型紫杉烷，尚未证明比母体化合物具有临床优势。
Zotero 插件